Anindita Tripathy1, Manoj Kumar Sahu2, Kanishka Uthansingh2, Ayaskanta Singh2, Jimmy Narayan2 and Ratna Kumari1*
1Disease Biology Lab, KIIT School of Biotechnology, KIIT University, Bhubaneswar,
2Department of Gastroenterology and Hepatobiliary Sciences, IMS and SUM Hospital, Bhubaneswar, India
*Corresponding Author: Ratna Kumari, Disease Biology Lab, KIIT School of Biotechnology, KIIT University, Bhubaneswar, India.
Received: January 02, 2020; Published: February 27, 2020
Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed primary liver cancer and is refractory to most of the chemotherapeutic drugs available. Multiple signalling pathways are deregulated in HCC, and two important developmental signalling pathways which are deregulated in HCC are Wnt and Hh signalling pathways. In various cancer models both pathways have been found to interact with each other at different levels and this interaction is known to play important role in the pathophysiology of those cancers like pancreatic cancer, colon cancer, and basal cell carcinoma. Previously we have shown that the Wnt and Hh pathways correlate positively and play an important role in the progression of hepatocarcinogenesis in rodent model. Our previously published data suggested that the investigation of cross-talk between these two pathways holds potential for identification of better HCC treatment strategies. In the present study we utilized pharmacological inhibitors of Wnt and Hh signalling pathways to unravel the functional interaction between these two pathways. We studied the impact of inhibition or up-regulation of Wnt signalling pathway on Hh signalling pathway outcome. We also investigated the chemo-preventive action of Sulindac Sulphide, a Wnt/b-catenin pathway inhibitor on tumorigenesis in animal model of hepatocarcinogenesis. Our study elaborated the nature of cross-talk between these two well known aberrant signalling pathways in HCC which would further pave the way for development of better combination therapy approach for targeting these two pathways in HCC.
Keywords: Hepatocellular Carcinoma; Sulindac Sulphide; KAAD-Cyclopamine; Wnt/β-catenin; Hh/Gli1
Citation: Ratna Kumari., et al. “The Therapeutic Relevance of Co-Targeting Wnt-Hh Signalling Pathways in Hepatocellular Carcinoma”. Acta Scientific Gastrointestinal Disorders 3.3 (2020): 32-40.
Copyright: © 2020 Ratna Kumari., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.